BACKGROUND: Invasive fungal infections (IFI) in immunocompromised patients are associated with significant morbidity and mortality, despite appropriate antifungal treatment and recovery from neutropenia. The outcome of these infections depends significantly on the overall state of immunosuppression, including mainly the phagocytic system (neutrophils and macrophages). Interferon-gamma (IFN-gamma), granulocyte-colony--stimulating factor (G-CSF) and granulocyte-macrophage-colony--stimulating factor (GM-CSF) are cytokines that enhance the activity of neutrophils and macrophages. METHODS: The authors reported 4 patients with leukemia and refractory invasive candidiasis or trichosporonosis despite 1-13 months of appropriate antifungal treatment. RESULTS: Cytokines were administered for 1.5-5 months without significant toxicity. For each patient, initiation of interferon-gamma plus a colony-stimulating factor resulted in a clinical response. The contribution of cytokines to control the fungal infection in these 4 patients was suggested by the strong inflammatory reaction observed in the 2 patients who had an immediate response (within 7 days of initiation of cytokine therapy) and by the good outcome in the 2 other patients in whom antifungal agents were discontinued at the start of cytokine therapy. CONCLUSIONS: These data suggested a potential role for immunomodulation in patients with leukemia with refractory invasive fungal infections.
BACKGROUND:Invasive fungal infections (IFI) in immunocompromised patients are associated with significant morbidity and mortality, despite appropriate antifungal treatment and recovery from neutropenia. The outcome of these infections depends significantly on the overall state of immunosuppression, including mainly the phagocytic system (neutrophils and macrophages). Interferon-gamma (IFN-gamma), granulocyte-colony--stimulating factor (G-CSF) and granulocyte-macrophage-colony--stimulating factor (GM-CSF) are cytokines that enhance the activity of neutrophils and macrophages. METHODS: The authors reported 4 patients with leukemia and refractory invasive candidiasis or trichosporonosis despite 1-13 months of appropriate antifungal treatment. RESULTS: Cytokines were administered for 1.5-5 months without significant toxicity. For each patient, initiation of interferon-gamma plus a colony-stimulating factor resulted in a clinical response. The contribution of cytokines to control the fungal infection in these 4 patients was suggested by the strong inflammatory reaction observed in the 2 patients who had an immediate response (within 7 days of initiation of cytokine therapy) and by the good outcome in the 2 other patients in whom antifungal agents were discontinued at the start of cytokine therapy. CONCLUSIONS: These data suggested a potential role for immunomodulation in patients with leukemia with refractory invasive fungal infections.
Authors: Theo S Plantinga; Melissa D Johnson; William K Scott; Leo A B Joosten; Jos W M van der Meer; John R Perfect; Bart Jan Kullberg; Mihai G Netea Journal: Med Mycol Date: 2012-06-04 Impact factor: 4.076
Authors: Karen Quillen; Edward Wong; Phillip Scheinberg; Neal S Young; Thomas J Walsh; Colin O Wu; Susan F Leitman Journal: Haematologica Date: 2009-12 Impact factor: 9.941
Authors: Eemke L Assendorp; Mark S Gresnigt; Evelien G G Sprenkeler; Jacques F Meis; Natasja Dors; Jan W M van der Linden; Stefanie S V Henriet Journal: Eur J Clin Microbiol Infect Dis Date: 2018-07-19 Impact factor: 3.267
Authors: Rebecca A Drummond; Jigar V Desai; Emily E Ricotta; Muthulekha Swamydas; Clay Deming; Sean Conlan; Mariam Quinones; Veronika Matei-Rascu; Lozan Sherif; David Lecky; Chyi-Chia R Lee; Nathaniel M Green; Nicholas Collins; Adrian M Zelazny; D Rebecca Prevots; David Bending; David Withers; Yasmine Belkaid; Julia A Segre; Michail S Lionakis Journal: Cell Host Microbe Date: 2022-05-13 Impact factor: 31.316
Authors: Corine E Delsing; Mark S Gresnigt; Jenneke Leentjens; Frank Preijers; Florence Allantaz Frager; Matthijs Kox; Guillaume Monneret; Fabienne Venet; Chantal P Bleeker-Rovers; Frank L van de Veerdonk; Peter Pickkers; Alexandre Pachot; Bart Jan Kullberg; Mihai G Netea Journal: BMC Infect Dis Date: 2014-03-26 Impact factor: 3.090